High Baseline Lipoprotein(a) Level as a Risk Factor for Coronary Artery Calcification Progression: Sub-analysis of a...

Area of Science:

• Cardiology
• Lipidology
• Preventive Medicine

Background:

• Lipoprotein(a) [Lp(a)] is a significant, independent predictor of cardiovascular disease (CVD).
• Understanding Lp(a)'s role in coronary artery calcification (CAC) progression is crucial, especially in patients with hypercholesterolemia receiving statin therapy.

Purpose of the Study:

• To investigate the association between baseline Lp(a) levels and CAC progression.
• To determine if Lp(a) is an independent predictor of CAC progression in hypercholesterolemic patients on statins.

Main Methods:

• Sub-analysis of a multicenter prospective study involving 147 hypercholesterolemic patients (Agatston score 1-999) on statin therapy.
• Patients were categorized based on annual CAC progression (Agatston score change).
• Logistic regression analysis was used to identify independent predictors of CAC progression, adjusting for traditional CVD risk factors.

Main Results:

• A higher proportion of patients with Lp(a) > 30 mg/dL showed significant CAC progression.
• Baseline Lp(a) > 30 mg/dL was an independent predictor of substantial annual CAC progression (Agatston score > 100; OR: 5.51, p=0.02).
• This association remained significant after adjusting for age, sex, diabetes, hypertension, smoking, BMI, and lipid-lowering medications.

Conclusions:

• Baseline Lp(a) levels > 30 mg/dL predict coronary artery calcification progression in hypercholesterolemic patients undergoing statin therapy.
• Lp(a) is a valuable biomarker for assessing CVD risk in this patient population, even with effective lipid management.
• Further research may explore targeted therapies for elevated Lp(a) to mitigate cardiovascular risk.